AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$BOLT

Nemec Sarah sold $26K of BOLT

Nemec Sarah (Senior VP, Finance and PAO) sold 7,842 shares of Bolt Biotherapeutics, Inc. (BOLT) at an average of $3.32 ($3.24–$3.77) across 3 trades over 2026-09-16 to 2026-09-18.

Original reporting
SEC EDGAR · Nemec Sarah
Published Sep 21, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Neutral
high confidence
Mentioned
$BOLT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

The sale is modest and unlikely to affect BOLT's stock price in the short term.

02

Market read

Limited relevance; primarily of interest to insiders and compliance monitors.

03

What to watch

Potential upcoming clinical data releases could change sentiment regardless of this sale.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$BOLTNeutralHigh confidence
Context

Senior VP of Finance sold 7,842 shares for $26K in a Form 4 filing.

Expected impact

No material price movement expected.

Evidence & confidence

The transaction amount is small relative to market cap and does not alter ownership significantly.

Market effects

Sector

None; biotech sector unchanged.

Regional

No regional effect.

Global

Insignificant.

Counterpoint

What could challenge this read

Even small insider sells can precede larger moves; monitor for further disposals.

Key entities

  • Company
    Bolt Biotherapeutics, Inc.

    Biotech firm developing therapies.

  • Insider
    Sarah Nemec

    Senior VP, Finance and PAO at Bolt Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

OCT 23
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K2 min
OCT 23
$BOLTMed

Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement

Bolt Biotherapeutics (BOLT) acquired Prana Therapies via a stock-for-stock deal, exchanging shares for Prana's equity. Bolt also secured $120 million in a private placement, issuing Series D preferred stock and warrants. The funds will support operations into 2028. Prana's co-founder, Sheila Gujrathi, joined Bolt's board as chief strategy officer. BOLT shares closed at $4.19 on Nasdaq.

rttnews.com1 min
OCT 23
$BOLTHighAI 8/10

Bolt Biotherapeutics acquires Prana in reverse merger deal

Bolt Biotherapeutics (BOLT) acquired Prana Therapies in a reverse merger, raising $120M with potential for $60M more. Post-merger, Prana shareholders own 51.7% of Bolt. The combined company will advance Prana's INSPIRE platform, with Phase 2 data expected in Q2 2027. Sheila Gujrathi, Prana's co-founder, joins Bolt's board.

investing.com2 min
OCT 23
$BOLTMedAI 8/10

A $120 million financing is expected to fund Bolt's operations into 2028

Bolt Biotherapeutics (BOLT) acquired Prana Therapies, securing $120M in financing, with up to $60M more possible. The deal advances Prana's pipeline, including PRA-216, a bispecific antibody in Phase 2 trials for asthma, COPD, and atopic dermatitis. Data from all trials is expected in Q2 2027. Dr. Sheila Gujrathi, Prana's co-founder, joins Bolt's executive team. The financing is expected to fund operations into 2028.

stocktitan.net2 min